Skip to main content

Breast Cancer Research and Treatment

Ausgabe 3/2018

Inhalt (27 Artikel)

Review

Prognostic value of baseline serum HER2 extracellular domain level with a cut-off value of 15 ng/mL in patients with breast cancer: a systematic review and meta-analysis

Zhuo Zhang, Chao Li, Hongwei Fan, Qian Xiang, Ling Xu, Qianxin Liu, Shuang Zhou, Qiufen Xie, Shuqing Chen, Guangyan Mu, Yimin Cui

Open Access Review

Oncoplastic Breast Consortium consensus conference on nipple-sparing mastectomy

Walter P. Weber, Martin Haug, Christian Kurzeder, Vesna Bjelic-Radisic, Rupert Koller, Roland Reitsamer, Florian Fitzal, Jorge Biazus, Fabricio Brenelli, Cicero Urban, Régis Resende Paulinelli, Jens-Uwe Blohmer, Jörg Heil, Jürgen Hoffmann, Zoltan Matrai, Giuseppe Catanuto, Viviana Galimberti, Oreste Gentilini, Mitchel Barry, Tal Hadar, Tanir M. Allweis, Oded Olsha, Maria João Cardoso, Pedro F. Gouveia, Isabel T. Rubio, Jana de Boniface, Tor Svensjö, Susanne Bucher, Peter Dubsky, Jian Farhadi, Mathias K. Fehr, Ilario Fulco, Ursula Ganz-Blättler, Andreas Günthert, Yves Harder, Nik Hauser, Elisabeth A. Kappos, Michael Knauer, Julia Landin, Robert Mechera, Francesco Meani, Giacomo Montagna, Mathilde Ritter, Ramon Saccilotto, Fabienne D. Schwab, Daniel Steffens, Christoph Tausch, Jasmin Zeindler, Savas D. Soysal, Visnu Lohsiriwat, Tibor Kovacs, Anne Tansley, Lynda Wyld, Laszlo Romics, Mahmoud El-Tamer, Andrea L. Pusic, Virgilio Sacchini, Michael Gnant

Open Access Review

Surgical options for male breast cancer

Ian S. Fentiman

Review

The St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017: Egyptian view

Hussein Khaled, Heba Gamal, Mohamed Lotayef, Michael Knauer, Beat Thürliman

Preclinical study

IgA Fc-folate conjugate activates and recruits neutrophils to directly target triple-negative breast cancer cells

Eric D. Frontera, Rafa M. Khansa, Dana L. Schalk, Lauren E. Leakan, Tracey J. Guerin-Edbauer, Manohar Ratnam, David H. Gorski, Cecilia L. Speyer

Preclinical study

A tandem duplication of BRCA1 exons 1–19 through DHX8 exon 2 in four families with hereditary breast and ovarian cancer syndrome

Chen Du, Dorothea Mark, Barbara Wappenschmidt, Beatrix Böckmann, Brigitte Pabst, Saki Chan, Han Cao, Susanne Morlot, Caroline Scholz, Bernd Auber, Kerstin Rhiem, Rita Schmutzler, Thomas Illig, Brigitte Schlegelberger, Doris Steinemann

Preclinical study

CCN6 regulates IGF2BP2 and HMGA2 signaling in metaplastic carcinomas of the breast

Emily R. McMullen, Maria E. Gonzalez, Stephanie L. Skala, Mai Tran, Dafydd Thomas, Sabra I. Djomehri, Boris Burman, Kelley M. Kidwell, Celina G. Kleer

Open Access Preclinical study

Micro-computed tomography enables rapid surgical margin assessment during breast conserving surgery (BCS): correlation of whole BCS micro-CT readings to final histopathology

David M. McClatchy III, Rebecca A. Zuurbier, Wendy A. Wells, Keith D. Paulsen, Brian W. Pogue

Clinical trial

Patients electing to have PET rather than surgery for operable breast cancer are a high risk of treatment failure

Robert Thomas, Rachel Rowell, Siobhan Crichton, Henry Cain

Clinical trial

Omega-3 fatty acid use for obese breast cancer patients with aromatase inhibitor-related arthralgia (SWOG S0927)

Sherry Shen, Joseph M. Unger, Katherine D. Crew, Cathee Till, Heather Greenlee, Julie Gralow, Shaker R. Dakhil, Lori M. Minasian, James L. Wade III, Michael J. Fisch, N. Lynn Henry, Dawn L. Hershman

Clinical trial

Prediction of postoperative disease-free survival and brain metastasis for HER2-positive breast cancer patients treated with neoadjuvant chemotherapy plus trastuzumab using a machine learning algorithm

Masahiro Takada, Masahiro Sugimoto, Norikazu Masuda, Hiroji Iwata, Katsumasa Kuroi, Hiroyasu Yamashiro, Shinji Ohno, Hiroshi Ishiguro, Takashi Inamoto, Masakazu Toi

Clinical trial

Effects of trastuzumab on locoregional recurrence in human epidermal growth factor receptor 2-overexpressing breast cancer patients treated with chemotherapy and radiotherapy

Seung Hyuck Jeon, Kyung Hwan Shin, Jin Ho Kim, Kyubo Kim, In Ah Kim, Kyung-Hun Lee, Tae-Yong Kim, Seock-Ah Im

Clinical trial

Only estrogen receptor “positive” is not enough to predict the prognosis of breast cancer

Jai Min Ryu, Hee Jun Choi, Isaac Kim, Se Kyung Lee, Jonghan Yu, Jee-Eun Kim, Byeong-il Kang, Jeong Eon Lee, Seok Jin Nam, Seok Won Kim

Epidemiology

A portrait of germline mutation in Brazilian at-risk for hereditary breast cancer

Ana Rafaela de Souza Timoteo, Ana Élida Menezes Magalhães Gonçalves, Lucas Amadeus Porpino Sales, Betina Menezes Albuquerque, Jorge Estefano Santana de Souza, Patrícia Cristina Pascoto de Moura, Marcos Alberto Arruda de Aquino, Lucymara Fassarela Agnez-Lima, Tirzah Braz Petta Lajus

Epidemiology

Obesity and mortality after locoregional breast cancer diagnosis

A. Holliston Moore, Amy Trentham-Dietz, Marguerite Burns, Ronald E. Gangnon, Caprice C. Greenberg, David J. Vanness, John Hampton, Xiao-Cheng Wu, Roger T. Anderson, Joseph Lipscomb, Gretchen G. Kimmick, Rosemary Cress, J. Frank Wilson, Susan A. Sabatino, Steven T. Fleming

Open Access Epidemiology

Time to death in breast cancer patients as an indicator of treatment response

Steven A. Narod, Vasily Giannakeas, Victoria Sopik

Epidemiology

Tumor grade and progesterone receptor status predict 21-gene recurrence score in early stage invasive breast carcinoma

Jing Li Huang, Scott Kizy, Schelomo Marmor, Ariella Altman, Anne Blaes, Heather Beckwith, Todd M. Tuttle, Jane Yuet Ching Hui

Open Access Epidemiology

High rate of occult cancer found in prophylactic mastectomy specimens despite thorough presurgical assessment with MRI and ultrasound: findings from the Hereditary Breast and Ovarian Cancer Registration 2016 in Japan

Hideko Yamauchi, Megumi Okawa, Shiro Yokoyama, Chizuko Nakagawa, Reiko Yoshida, Koyu Suzuki, Seigo Nakamura, Masami Arai

Epidemiology

Young age at diagnosis is associated with worse prognosis in the Luminal A breast cancer subtype: a retrospective institutional cohort study

Zhiyang Liu, Zeyad Sahli, Yongchun Wang, Antonio C. Wolff, Leslie M. Cope, Christopher B. Umbricht

Epidemiology

Prognosis in patients diagnosed with loco-regional failure of breast cancer: 34 years longitudinal data from the Stockholm–Gotland cancer registry

Claudette Falato, Sara K. Taylor, Robert Szulkin, Axel Nordblom, Louise Eriksson, Anastasios Sofiadis, Irma Fredriksson, Johan Hartman, Jonas Bergh, Theodoros Foukakis

Open Access Brief Report

Extracellular vesicles from triple-negative breast cancer cells promote proliferation and drug resistance in non-tumorigenic breast cells

Patricia Midori Murobushi Ozawa, Faris Alkhilaiwi, Iglenir João Cavalli, Danielle Malheiros, Enilze Maria de Souza Fonseca Ribeiro, Luciane Regina Cavalli

Brief Report

Epigenetic modulation of FOXM1-gene interacting network by BET inhibitors in breast cancer

Javier Pérez-Peña, Balázs Győrffy, Eitan Amir, Atanasio Pandiella, Alberto Ocaña

Brief Report

Effectiveness and tolerability of neoadjuvant pertuzumab-containing regimens for HER2-positive localized breast cancer

Laura Spring, Andrzej Niemierko, Stephanie Haddad, Megan Yuen, Amy Comander, Kerry Reynolds, Jennifer Shin, Atul Bahn, Elena Brachtel, Michelle Specht, Barbara L. Smith, Alphonse Taghian, Rachel Jimenez, Jeffrey Peppercorn, Steven J. Isakoff, Beverly Moy, Aditya Bardia

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.